- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- ABT-751
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 17
- States / cities
- Miami, Florida • New Port Richey, Florida • Chicago, Illinois + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 281
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Constipation, Bowel Obstruction, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Breast Neoplasms, Metastases
- Interventions
- E7070
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Sedona, Arizona + 31 more
- Conditions
- Chemotherapy-Induced Alopecia
- Interventions
- Compound 31543 Calcitriol 5 μg/mL, Compound 31543 Calcitriol 10 μg/mL, Compound 31543 Calcitriol 20 μg/mL, Compound 31543 Calcitriol 40 μg/mL, Compound 31543 Calcitriol 60 ug/mL, Compound 31543 Calcitriol 80 μg/mL
- Drug
- Lead sponsor
- BPGbio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
- Conditions
- Prostate Cancer Metastatic
- Interventions
- DOCETAXEL (XRP6976), CABAZITAXEL (XRP6258), Prednisone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 10 more
- Conditions
- Breast Cancer, Metastases
- Interventions
- Ixabepilone
- Drug
- Lead sponsor
- R-Pharm
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 17
- States / cities
- La Verne, California • Meriden, Connecticut • Jacksonville, Florida + 14 more
- Conditions
- Prostate Cancer
- Interventions
- Immunotherapy allogeneic GM-CSF secreting cellular vaccine, Chemotherapy (docetaxel and prednisone)
- Biological · Drug
- Lead sponsor
- Cell Genesys
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 43
- States / cities
- Anchorage, Alaska • Fort Smith, Arkansas • Loma Linda, California + 32 more
- Conditions
- Prostate Cancer
- Interventions
- Panzem® NCD
- Drug
- Lead sponsor
- CASI pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Supportive, Ill-defined Sites
- Interventions
- paclitaxel, docetaxel, taxane, taxane
- Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Pancreatic Cancer
- Interventions
- TPI 287
- Drug
- Lead sponsor
- Cortice Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 3
- States / cities
- Rancho Mirage, California • Baltimore, Maryland • Bethesda, Maryland
- Conditions
- Alzheimer's Disease
- Interventions
- TPI-287 2 mg/m2, TPI-287 6.3 mg/m2, TPI-287 20 mg/m2, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 50 Years to 82 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Prostate Cancer, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- laboratory biomarker analysis, questionnaire administration, doxorubicin-GnRH agonist conjugate AEZS-108
- Other · Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Gastro-Oesophageal Cancer
- Interventions
- Regorafenib, Nivolumab, Docetaxel, Paclitaxel, Irinotecan, Trifluridine/Tipracil
- Drug · Biological
- Lead sponsor
- Australasian Gastro-Intestinal Trials Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Sioux City, Iowa + 3 more
- Conditions
- Ovarian Cancer
- Interventions
- Decitabine, Carboplatin, Paclitaxel, Selinexor
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
- Interventions
- Olvi-Vec, Platinum-doublet with or without bevacizumab
- Biological · Drug
- Lead sponsor
- Genelux Corporation
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Newport Beach, California • Orlando, Florida
- Conditions
- Breast Cancer, Fatigue, Hypothyroidism
- Interventions
- physiologic testing, fatigue assessment and management, management of therapy complications
- Other · Procedure
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 20 Years to 80 Years · Female only
- Enrollment
- 541 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2015
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Greeley, Colorado • Loveland, Colorado + 28 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Abemaciclib, Trastuzumab Emtansine
- Drug · Biological
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Yuma, Arizona • Jacksonville, Florida • Urbana, Illinois + 3 more
- Conditions
- Ovarian Neoplasms
- Interventions
- Sorafenib (Nexavar, BAY43-9006), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 4
- States / cities
- La Jolla, California • Jacksonville, Florida • Augusta, Georgia + 1 more
- Conditions
- Advanced Solid Tumor, Gynecologic Cancer
- Interventions
- Lucitanib, Nivolumab
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 9 more
- Conditions
- Breast Neoplasms
- Interventions
- epothilone b
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • New Brunswick, New Jersey
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- eribulin mesylate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Duarte, California • Pittsburgh, Pennsylvania
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- PS-341 (Bortezomib), Carboplatin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Paclitaxel
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 167 more
- Conditions
- Breast Cancer
- Interventions
- Mathematical modeling to predict response to chemotherapy
- Other
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico